Monte Rosa at Guggenheim healthcare conference: pipeline gains momentum
At a glance
- $GLUE today−0.98%last $9.07
- Vs industry peers−1.31 pts6-peer median +0.32% · behind
- Since Nov 9−13.8%from the first trade after the story
- 52-week range2.7% above low$8.83 – $25.77
- Coverage1 this week2 in 30 days · too few stories to call a pace
- Sector scannerCalmHealth Care
Nothing reported about monte rosa across key-person, legal, regulatory, security, operational or financial-integrity risk in three weeks of coverage and 30 days of SEC filings.
Ranges are one standard deviation of volatility around the latest close — about 1 week in 3 moves further. Not a forecast or investment advice.
What it means
- What to watch: A drugmaker's fate can hinge on a single product — and a single approval or trial result can shift its valuation overnight.
- How the stock is trading: $GLUE -0.98% in the latest session.
- Timing: It was published before the opening bell, so the next session was the first chance to trade on it.
Where the stock stands
Monte Rosa Therapeutics ($GLUE) edged down 0.98% to $9.07 in the latest session. Over the past month it is down 14.9%. It now sits 65% under the 52-week high of $25.77 and 2.7% above the year's low of $8.83, close to the bottom of its range. It has been a volatile year: the high was 2.9 times the low, so moves this size are not unusual for it.
How much coverage it is getting
Wook has filed 2 stories on Monte Rosa Therapeutics in the last 30 days, 1 of them this week. That is running well ahead of normal: over the month it has averaged less than one a week. Going by their wording, 1 read bullish, 1 neutral and 0 bearish. This one reads bullish too, in line with most of them. Investing.com wrote 2 of them; the rest came from other outlets.
The bigger picture
In healthcare, timing is everything — from trial updates to regulatory decisions, one event can tilt the market for a whole sector. Health Care reads calm on Wook's supply-chain scanner today, with no unusual stress in the filings and disclosures it watches.
What to watch next
The $GLUE page has all the charts, filings, and models to back up the story. Comparing coverage from different outlets helps spot trends or repetition. Wook AI is here to crunch the numbers and show how far $GLUE has come — or how far it has to go.
Discussion
No one has weighed in yet. Start the discussion on this story.
What happened after this published
Investing.com published this on November 9, 2026. $GLUE has moved -13.78% ($10.52 to $9.07). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.
